A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors.
Our approach addresses the central problem of cancer research: tumor-targeted killing. We focus on targets either lost or gained in cancer cells, potentially creating breakthrough therapies to treat most cancers.
The company was founded in 2018 by Alexander Kamb, Michael Gallo and Paul Kang and raised a Series A financing of $57 million (The Column Group, Vida Ventures, Samsara Capital and Nextech Invest).